












Mark Feitelson
Founder at SFA Therapeutics
Mark Feitelson received his Ph.D. in Microbiology/Immunology from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations. He has more than 150 publications and 180 abstracts. He is also CSO of SFA Therapeutics.
Previously at

Temple University
Thomas Jefferson University Hospital

Thomas Jefferson University

Fox Chase Cancer Center

Stanford University

Stanford University School of Medicine
Alumnus of

David Geffen School of Medicine at UCLA

University of California, Irvine

Cypress College